Table 3 Preclinical studies of nanoparticles in the treatment of lung cancer

ZnO nanoparticles

SCLC

i.v

In vivo

Orthotopic mouse model

Toxic to mouse lung cancer cells without any side effects after the trial

(Tanino et al. 2020)

PD-L1 antibody nanoparticles

A549

Small animal imaging method

In vivo

Nude mouse model

Good targeting to A549 tumor cells and easy to be absorbed

(Wei et al. 2021)

Glutathione-responsive polyurethane nanoparticles

A549

i.v

In vivo

Xenograft mouse model

Shows growth inhibitory effect on lung tumors

(Iyer et al. 2020)

Multifunctional Chitosan Poly Nanoparticles

A549

i.v

In vivo

BALB/c mouse model

Methotrexate accumulates at tumor sites and significantly inhibits tumor growth

(Guo et al. 2018)

Magnetic Nanoparticles

A549

In vitro

Xenograft mouse model

Nanoparticles are cytotoxic and enhance tumor cell uptake

(Baskar et al. 2017)

SORA-CRIZ@NPs

A549

i.v

In vivo

Xenograft mouse model

Significantly reduces tumor survival with minimal side effects

(Zhong et al. 2021)

MUC-1 Peptide-PLGA-NA-NPs

A549

In vitro

Xenograft mouse model

Enhanced cellular uptake

(Jyoti et al. 2020)

LF-CaP-Ls

Lung cancer

i.v

In vivo

Mouse model

Effective on mouse tumors, reduce tumor progression, and have basic anti-cancer effects

(Sethuraman et al. 2021)

Etoposide and Cisplatin Dual Drug-loaded Nanoparticles

NSCLC

In vivo

Mouse model

More effective and less toxic than free drug

(Zhang et al. 2021)

Nanoparticle-bound CpG

NSCLC-344SQ KAL-LN2E1

Oral tracheal drip

In vivo

Mouse Orthotopic Metastasis Model

Extend the retention time of CpG in the lung, improve the anti-tumor factor of the lung, and have incidental therapeutic effect on systemic diseases

(Perry et al. 2020)

HA-PEI

NSCLC

i.p

In vivo

Genetically engineered mouse models

HA-PEI successfully transfected mouse and mouse lung TAM

(Parayath et al. 2018)